Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:7954982.
doi: 10.1155/2016/7954982. Epub 2016 Jun 14.

Effect of TongXie-YaoFang on Cl(-) and HCO3 (-) Transport in Diarrhea-Predominant Irritable Bowel Syndrome Rats

Affiliations

Effect of TongXie-YaoFang on Cl(-) and HCO3 (-) Transport in Diarrhea-Predominant Irritable Bowel Syndrome Rats

Xiaofang Lu et al. Evid Based Complement Alternat Med. 2016.

Abstract

TongXie-YaoFang (TXYF) can effectively alleviate the symptoms of diarrhea-predominant irritable bowel syndrome (D-IBS) patients. However, the curative mechanism has not been fully clarified. The study was designed to investigate the effect of TXYF on the colonic ion transport induced by serotonin (5-HT) in D-IBS rats. A method of multiple stress (neonatal maternal separation (NMS) combined with restraint stress (RS)) was used to induce the D-IBS model. The model rats were randomly divided into two groups: NMS + RS group and TXYF-formula group, and the normal control (no handling) rats were classified as NH group. In the NMS + RS group, the change of short-circuit current (ΔI sc) induced by 5-HT was lower than that in the NH and TXYF-formula groups. After removing of the extracellular Cl(-) or HCO3 (-) or basolateral Na(+) or blocking the cystic fibrosis transmembrane conductance regulator (CFTR), Na(+)-K(+)-2Cl(-) cotransporter (NKCC), Na(+)-HCO3 (-) cotransporter, Cl(-)/HCO3 (-) exchanger, K(+) channel, or Na(+)/K(+)-ATPase, respectively, there was no difference in 5-HT-induced ΔI sc among the three groups. These data suggest that TXYF can regulate 5-HT-induced Cl(-) and HCO3 (-) secretion, possibly mediated by the combined action of CFTR, NKCC, Na(+)-HCO3 (-) cotransporter, Cl(-)/HCO3 (-) exchanger, K(+) channel, and Na(+)/K(+)-ATPase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of basal electrophysiological properties and 5-HT-induced ΔI sc of colonic mucosa among the three groups (means ± SEM, n = 18). Basal I sc (a); basal potential difference (PD) (b); basal transmembrane resistance (TR) (c); ΔI sc induced by 5-HT (d). P < 0.01 versus NH group; P < 0.01 versus NMS + RS group.
Figure 2
Figure 2
Comparison of 5-HT-induced ΔI sc of colonic mucosa in Cl-free, HCO3 -free, or Cl- and HCO3 -free (a); apical Na+-free (b); basolateral Na+-free (c) K-HS among the three groups (means ± SEM, n = 6). P < 0.01 versus NH group; P < 0.05 versus NMS + RS group.
Figure 3
Figure 3
Comparison of 5-HT-induced ΔI sc of colonic mucosa after apical application of DPC, a nonselective Cl channel blocker; glibenclamide or CFTR(inh)-172, the cAMP-independent Cl channel blockers; and DIDS, a Ca2+-independent Cl channel blocker (a); apical application of amiloride, an epithelial Na+ channel blocker (b); basolateral application of BaCl2, a K+ channel inhibitor (c) among the three groups (means ± SEM, n = 6). P < 0.05 and ∗∗ P < 0.01 versus NH group; P < 0.05 and ▲▲ P < 0.01 versus NMS + RS group.
Figure 4
Figure 4
Comparison of 5-HT-induced ΔI sc of colonic mucosa in the basolateral presence of Na+-K+-2Cl cotransporter (NKCC) inhibitor, bumetanide; Na+-HCO3 cotransporter or Cl/HCO3 exchanger inhibitor, SITS; Na+/K+-ATPase inhibitor, ouabain, among the three groups (means ± SEM, n = 6).

Similar articles

Cited by

References

    1. Drossman D. A. Introduction. The Rome Foundation and Rome III. Neurogastroenterology and Motility. 2007;19(10):783–797. doi: 10.1111/j.1365-2982.2007.01001.x. - DOI - PubMed
    1. Yao X., Yang Y. S., Cui L.-H., et al. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. Journal of Gastroenterology and Hepatology. 2012;27(4):760–765. doi: 10.1111/j.1440-1746.2011.06930.x. - DOI - PubMed
    1. Singh P., Staller K., Barshop K., et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World Journal of Gastroenterology. 2015;21(26):8103–8109. doi: 10.3748/wjg.v21.i26.8103. - DOI - PMC - PubMed
    1. Nee J., Zakari M., Lembo A. J. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy. 2015;16(18):2781–2792. doi: 10.1517/14656566.2015.1101449. - DOI - PubMed
    1. Lävo B., Stenstam M., Nielsen A.-L. Loperamide in treatment of irritable bowel syndrome—a double-blind placebo controlled study. Scandinavian Journal of Gastroenterology. 1987;22(130):77–80. doi: 10.3109/00365528709091003. - DOI - PubMed

LinkOut - more resources